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ABSTRACT 
 
Activating mutations in the PI3K/AKT pathway are present in majority of breast cancer. The 
gain of function mutation E17K of AKT1, was found in 8% of breast cancers, especially 
ductal carcinomas, but several studies performed so far have failed to define the real role of 
this mutation in the breast tissue trnsformation. To investigate the role of the AKT1
E17K 
in 
breast tumorigenesis, we explored the phenotype of a new mouse model which express the 
mutant transgene in mammary epithelium. The expression of AKT1
E17K
 enhances the activity 
of the kinase and the phosphorilation status of downstream substrates, such as FOXO1 and 
GSK3α/β. In addition, transgenic mice showed an increased cellularity 8-10 times higher than 
control mice breast tissues. Moreover 70% of transgenic mice expressing the mutant form of 
AKT1 develop ductal carcinomas from medium to high grade. We have identified also the 
contribution of AKT1
E17K
 in the generation and maintenance of putative breast cancer stem 
cells. Finally, using a pharmacological study, we were able to slow down tumor formation by 
inhibiting downstream effect of AKT1 pathway. All together these data have allowed us to 
demonstrate that AKT1
E17K
 is itself capable to induct the onset of ductal carcinoma in 
transgenic mice. 
 
 
 
 
 
 
 
 6 
RIASSUNTO 
Mutazioni attivanti nel pathway PI3K/AKT sono stati trovati nella maggior parte dei 
carcinomi mammari. La mutazione E17K nel gene AKT1, che ne determina un guadagno di 
funzione è stata trovata nell’8% dei casi di cancro al seno, specialmente in carcinomi duttali, 
ma i diversi studi condotti finora non sono riusciti a definire il vero ruolo di questa mutazione 
nel processo di trasformazione tumorale del tessuto mammario. Per studiare il ruolo di 
AKT1
E17K
 nella tumorigenesi mammaria, abbiamo esplorato il fenotipo di un nuovo modello 
murino che esprime il transgene in maniera specifica nell’ epitelio mammario. L’espressione 
di AKT1
E17K
 aumenta l’attività della chinasi e dunque il grado di fosforilazione di substrati a 
valle, come FOXO1 e GSK3α/β.inoltre i topi transgenici mostrano una cellularità tissutale 8-
10 volte superiore a quella dei topi di controllo. Il 70% dei topi transgenici che esprimono la 
forma mutante di AKT1  sviluppano carcinoma duttale ad alto e medio grado. Abbiamo anche 
identificato il contributo di  AKT1
E17K
 nella generazione e mantenimento delle putative cellule 
tumorali staminali mammarie. Infine, medinate uno studio farmacologico siamo riusciti a 
ritardare la formazione dei tumori inibendo il pathway a valle di AKT1. Tutti questi dati ci 
hanno consentito di dimostrare che AKT1
E17K
 è di per sé capace di indurre l’insorgenza di 
carcinoma mammario duttale in topi transgenici. 
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INTRODUCTION 
BREAST CANCER 
EPIDEMIOLOGY 
Breast cancer is the third most frequent cancer in the world (after lung and gastric cancer) and 
most common female malignancy. It is the fifth cause of death from cancer overall (after lung, 
stomach, colorectal and liver cancers) and leading cause of cancer death among females, 
accounting for 23% of the total cancer cases and 14% of the cancer deaths. [1][2] The areas of 
high risk are represented by the populations of North America, Europe and Australia, where 
6% of women develop invasive breast cancer before age 75. The risk of breast cancer is low in 
the less developed regions of sub-Saharan Africa and Southern and Eastern Asia, including 
Japan, where the probability of developing breast cancer by age 75 is one third respect to rich 
countries. [3] In 2013, in USA, 232.340 new cases of invasive breast cancer have been 
diagnosed among women, as well as 64.640 additional cases of in situ breast cancer. In 2013, 
have been estimated approximately 39.620 women deaths from breast cancer and 2.240 men 
have been diagnosed with breast  cancer and 410 men are dead from the disease. (figure 1). [4] 
 
 
 
Figure 1: estimated new female in situ and invasive breast cancer cases and death by age, US, 2013. [4] 
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HISTOLOGICAL CLASSIFICATION 
Breast cancer originates from the epithelial cells of the glandular tree and may give rise to 
different histotypes. The most common are the lobular and ductal carcinomas, of which there 
are in situ and invasive forms. 
 
IN SITU BREAST CANCER 
- Ductal carcinoma in situ (DCIS) is the most common type of in situ breast cancer, 
accounting for about 83% of in situ cases diagnosed during 2006-2010. DCIS may or may not 
progress to invasive cancer; in fact, it consists of cancerous cells that proliferate within the 
lumens of the breast duct with no invasion. It grows so slowly that even without treatment 
does not affect the women health. [5][6] Clinical studies suggest, however, that about one-
third, and possibly more, of DCIS cases will progress to invasive cancer if left untreated. [5]  
- Lobular carcinoma in situ (LCIS, also known as lobular neoplasia) is not a true cancer or 
precancer, but an indicator of increased risk for developing invasive cancer. It is represented 
by the presence of unusual cells in the lobules of the breast. LCIS is much less common than 
DCIS, accounting for about 12% of female in situ breast cancers diagnosed during 2006-2010. 
[7]  
- Other in situ breast cancers have characteristics of both ductal and lobular carcinomas or 
have unknown origins.[4] 
 
INVASIVE BREAST CANCER 
Invasive breast carcinoma is a group of malignant epithelial tumors characterized by invasion 
of adjacent tissues and a marked tendency to metastasize to distant sites. Invasive breast 
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carcinomas exhibit a wide range of morphological phenotypes and specific histopathological 
types have particular prognostic or clinical characteristics. [3] 
INVASIVE DUCTAL CARCINOMA 
Invasive ductal carcinoma (IDC) is the most common histologic type of invasive breast 
cancer and comprises 70% to 80% of breast cancer cases. Invasive ductal carcinoma starts 
in a milk duct of the breast, breaks through the wall of the duct, and grows into the breast 
fatty tissue. It is able to spread to other parts of the body through the lymphatic system and 
bloodstream. About 8 of 10 invasive breast cancers are infiltrating ductal carcinomas. It 
can occur in different histological subtypes: tubular, medullary, mucinous, papillary and 
cribiform. [8] 
INVASIVE LOBULAR CARCINOMA 
Invasive lobular carcinoma (ILC), is the second most common type of breast accounting 
about 8-14% of all invasive breast cancers are invasive lobular carcinomas. [9][10]  It 
begins in the milk-producing lobules and spreads to the surrounding breast tissues, lymph 
nodes and possibly to other areas of the body. There are different subtypes of invasive 
lobular carcinoma (ILC) that are based on specific morphological properties: solid, 
alveolar, tubuloalveolar, pleomorphic, signet ring cell. [8] 
 
GENETICS OF BREAST CANCER  
Breast cancer is a heterogeneous disease caused by progressive accumulation of genetic 
aberrations, including point mutations, chromosomal amplifications, deletions, 
rearrangements, translocations, and duplications.[11] Germline mutations account for only 
about 10% of all breast cancers, while the vast majority of breast cancers occurs 
sporadically and is attributed to somatic genetic alterations. In familiar forms, breast 
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cancer susceptibility genes can be categorized into three classes according to their 
frequency and level of risk that they confer:  
- rare high-penetrance genes, in particular BRCA1 and BRCA2, which encode large 
proteins with multiple functions which act as classic tumor suppressor genes that maintain 
genomic stability by facilitating double-strand DNA repair through homologous 
recombination. [12]. When loss of heterozygosis (LOH) occurs via loss, mutation or 
silencing of the wild type BRCA1 and BRCA2 allele, the resultant defective DNA repair 
system leads to rapid acquisition of additional mutations, particularly during DNA 
replication. [13]. BRCA1 and BRCA2 mutations account for approximately half of all 
dominantly inherited hereditary breast cancers. These mutations confer a relative risk of 
breast cancer 10 to 30 times higher that of women in the general population, resulting in a 
nearly 85% lifetime risk of breast cancer development. [14]. Other high-penetrance genes 
are TP53, PTEN, STK11/LKB1, and CDH1. These high-penetrance genes confer an eight-
ten fold increase in risk of breast cancer as compared to non- carriers, but they collectively 
account for less than 1% of cases of breast cancer. Like BRCA1 and BRCA2, these genes 
are inherited in an autosomal dominant manner and function as tumor suppressors. [15]. 
- rare intermediate-penetrance genes. Four genes that confer an elevated but moderate risk of 
developing breast cancer have been identified, namely CHEK2, ATM, BRIP1, and PALB2, 
involved in signal transduction and DNA repair. Each of these genes confers approximately a 
two-three fold relative risk of breast cancer.[13]. 
- common low-penetrance genes and loci, include approximately ten different alleles and loci 
in 15% to 40% of women with breast cancer. [14] Despite their frequency, the relative risk of 
breast cancer conferred by any one of these genetic variants alone is minimal, less than 1.5 
fold.[16] Nevertheless, these alleles and loci may become clinically relevant in interaction 
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with other high-, moderate-, and low-risk genes; these additive or multiplicative relationships 
could account for a measurable fraction of population risk.  
For example, association studies of FGFR2 and MAP3K1 within BRCA families showed that 
these single nucleotide polymorphisms (SNPs) conferres an increased risk in the presence of 
BRCA2 mutations. Recent studies suggest that microRNA (miRNA) SNPs may also contribute 
to breast cancer susceptibility, and miRNAs appear to regulate many tumor suppressor genes 
and oncogenes via degradation of target mRNAs or repression of their translation. [13] 
The vast majority of breast cancers are sporadic, caused by accumulation of several somatic 
genetic alterations. Recent data suggest that a typical individual breast cancer harbors 
anywhere from 50 to 80 different somatic mutations. [11] Many of these mutations occur as a 
result of erroneous DNA replication; others may occur through exposure to exogenous and 
endogenous mutagens. [13] Among gene amplifications, the most frequent in breast cancer 
regard HER-2/Neu, growth receptor that activates the Ras-MEK and PI3K pathway, amplified 
in about 13% of the breast cancer. Cyclin D1, amplified in about 10-12% of the breast cancers, 
WIP1 (13%) and GASC1, amplified in about 5-10% of total breast cancers and in the 20-25% 
of the basal breast cancer. [17] 
Inactivation of gene functions by deletion or other mechanisms commonly occurs in PTEN 
and p53 in HER2/neu positive breast cancers, triple negative breast cancers, and BRCA-
associated breast and ovarian cancers. PI3K ampliﬁcations and activating mutations are 
common in breast cancers and several genes such as AKT and STAT3 are often expressed at 
high activities but without detectable ampliﬁcations of those genes. [18] Epigenetic 
alterations, such as methylation of cytosine residues in CpG dinucleotides, can bring about 
gene inactivation, for example p16 gene in breast cancers.  [17] A substantial number of these 
somatic mutations sort out among a much smaller number of biological  groups and cell 
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signaling pathways that are known to be pathogenetic in breast cancer, thereby vastly reducing 
the complexity of the genomic landscape. Examples of such pathways include interferon 
signaling, cell cycle checkpoint, BRCA1/2- related DNA repair, p53, transforming growth 
factor-β (TGF-β) signaling, Notch, epidermal growth factor receptor (EGFR), FGF, ERBB2, 
RAS, and PI3K-AKT. [13] 
 
MOLECULAR CLASSIFICATION 
The accumulation of different mutations has significant effects on the expression of important 
tissue-specific genes. Distinct molecular subtypes of breast cancer have been identified using 
biological markers, including the presence or absence of estrogen receptors (ER+/ ER-), 
progesterone receptors (PR+/PR-), and human epidermal growth factor receptor 2 
(HER2+/HER2-). [4][13] 
We can distinguish four different types of breast cancer: luminal A, luminal B, Basal-like and 
HER2 enriched. (figure 2) 
Luminal A tumors have high expression of ER and ER-regulated genes, low expression of the 
HER2 cluster and proliferation-associated genes. Luminal B tumors tend to be highly 
proliferative, express mutant form of TP53, show lower expression of ER and ER-regulated 
genes and can be HER2+ or HER2-. [19][20] Basal-like breast cancer are referred to as “triple 
negative” because they are ER-, PR-, and HER2-. The basal- like subtype is characterized by 
low expression of the luminal genes, low expression of the HER2 gene cluster, high 
expression of the proliferation cluster, and high expression of a unique cluster of genes called 
the basal cluster (cytokeratins 5, 6, 14,17, c-Kit; Vimentin; P-Cadherin). Several risk factors 
for developing basal-like tumors have been identiﬁed, among which the most interesting being 
the link between the basal-like subtype and BRCA1 mutation carriers. [19] 
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The HER2-enriched subtype is relatively infrequent (10% of all breast cancers). This subtype 
shows elevated expression of HER2 and many other genes that reside near HER2 in the 
genome (GRB7) and do not express hormone receptors (ER- and PR-). [4] [19]  
 
Figure 2: Classification algorithm for molecular subtyping. [20] 
 
BREAST CANCER METASTASIS 
Metastatic breast cancer is defined by tumor spread beyond the breast, chest wall, and regional 
lymph nodes. Tumor dissemination can occur through blood and lymphatic vessels and via 
direct extension through the chest wall. The most common sites for breast cancer metastasis 
include the bone, lung, liver, lymph nodes, chest wall, and brain. [13]  (figure 3) 
 
 
Figure 3:Most common metastasis sites of breast cancer at autopsy. Primary breast cancer cells metastasize through the blood vessels to 
various distant organs, preferentially, to the lung, liver and bones. Patients frequently develop metastases at multiple sites. [21] 
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An increased likelihood of visceral metastases and a particularly poor prognosis are associated 
with the lack of estrogen receptor (ER) and progesterone receptor (PR) expression in breast 
cancer while triple-negative breast cancer is accompanied by distant, hematogenous metastasis 
that usually occur in the first five years after the initial diagnosis and are associated with 
relatively short relapse-free and overall survival times. [22]  
Hormone receptor–positive tumors are more likely to spread to bone as the initial site of 
metastasis; hormone receptor–negative and/or HER2-positive tumors are more likely to recur 
initially in viscera. [13][22] Lobular (as opposed to ductal) cancers are more often associated 
with serosal metastases to the pleura and abdomen.[13] Anyway, bone is the most commonly 
observed site for distant metastasis, around 70% of patients have lesions at bone and is the 
location of 30–40% of first tumor recurrence. [22] [23] Has been recently suggested that a 
cellular subpopulation with stem cell (SC)-like features, known as cancer SCs (CSCs), is 
critical for tumor generation and maintenance, and responsible for breast cancer metastasis. 
Indeed, it is conceivable that several of the traits ascribed to CSCs may provide them with the 
potential to occupy and prosper at distant sites. [24] 
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BREAST CANCER STEM CELLS 
Cancer stem cells (CSCs) are tumor cells with enhanced capacity for tumor generation. CSCs 
possess several fundamental attributes similar to normal adult stem cells. They are capable of 
dividing asymmetrically to produce one stem cell, characterized by self-renewal, and one 
progenitor cell, which allows to produce phenotypically diverse cancer cells that constitute 
tumors. [25] In breast cancer has been isolated a small population of tumorigenic cells with 
stem cell (SC)-like features, capable of regenerating the phenotypic heterogeneity of the 
original tumor when injected subcutaneously into NOD/SCID mice. [26][27] These breast 
cancer stem cells (BCSCs) are characterized by the cell-surface markers ESA
+
/CD44
+
/CD24
-
/low
 ,  devoid of the expression of the lineage markers CD2, CD3, CD10, CD 16, CD18, CD31, 
CD64, and CD140b (Lin
−
) and bear high ALDH1 activity. [25][26][28] Putative breast CSCs 
have also been isolated from patient samples after in vitro propagation and from breast cancer 
cell lines, through their ability to proliferate in suspension as non adherent spheres 
(mammospheres). Because the capacity to form mammospheres is increased in early 
progenitor/stem cells, this system has been widely used as an indirect measurement of the 
number of cells with self-renewal capability. [29] The origin of breast CSCs is controversial. 
Current experimental evidence supports two different, but not exclusive, theories (figure 4).  
Figure 1. Or igin of the breast cancer  stem cells (BCSCs)
BCSCs may arise from normal mammary stem cells (A) or from non-stem tumor cells that
have gained the ability for self-renewal (B) by epithelial to mesenchymal transition (EMT)
and oncogenic transformation. Both of these hypotheses consider that the phenotypic
characteristics of BCSCs are caused by genetic alterations and/or EMT. As result, BCSCs
display alterations in signaling pathways controlling the cell cycle, differentiation, and
survival (C).
Velasco-Velázquez et al. Page 10
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Figure 4. Origin of the breast cancer stem cells (BCSCs). BCSCs may arise from normal mammary stem cells (A) or from non-
stem tumor cells that have gained the ability for self-renewal (B) by epithelial to mesenchymal transition (EMT) and oncogenic 
transformation. Both of these hypotheses consider that the phenotypic characteristics of BCSCs are caused by genetic alterations 
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and/or EMT. As result, BCSCs display alterations in signaling pathways controlling the cell cycle, differentiation, and survival 
(C). [25] 
 
One theory proposes that CSCs resulted from the deregulation of normal stem cell self-
renewal and differentiation pathways, resulting in cancer cells with both self-renewal and 
differentiation capabilities. A second theory suggests that BCSCs develop from epithelial-
mesenchymal transition (EMT). Cells that have undergone EMT are susceptible to 
transformation and have many characteristics and behaviors similar to those of normal and 
neoplastic stem cells. [25]  
BCSCs are characterized from the deregulation of different pathways implicated in the 
regulation of BCSCs self-renewal and differentiation. [30] A number of signaling pathways 
have been found to play a role in mammary stem cell self-renewal, including Wnt, Notch, and 
Hedgehog. In addition, the PTEN (phosphatase and tensin homolog deleted on chromosome 
10) tumor suppressor gene, one of the most frequently mutated genes in human malignancies, 
has also been suggested to play a role in stem cell self-renewal. In particular, in vitro and in 
vivo evidence revealed the importance of PTEN/PI3-K/Akt/Wnt/β-catenin pathway in BCSCs 
biology, in fact have been demostrated that active AKT phosphorylates GSK3β and thereby 
the Wnt pathway. [25][31] BCSCs have a great importance for the clinic and therapy, several 
studies have demonstrated that these cells are responsible for resistance to chemo- and 
radiotherapy, (es. for overexpression of Notch-1) and metastatic dissemination of tumors (es. 
for overexpression of genes that promote cell motility, invasion). The chemio- and radio- 
resistance is not a universal characteristic of BCSCs, in fact, BCSC population within a triple 
(estrogen receptor (ER), progesterone receptor (PR) and HER-2) negative cell line can be 
depleted by radiotherapy and several drugs tested clinically have shown activity against 
BCSCs. [32] 
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RISK FACTORS FOR BREAST CANCER  
Multiple factors are associated with an increased risk of developing breast cancer, including 
increasing age, exposure to female reproductive hormones (both endogenous and exogenous) 
and reproductive history, dietary and lifestyle factors, environmental factors and familial 
factors and inherited predisposition. The majority of these factors convey a small to moderate 
increase in risk for any individual woman. [13] 
- increasing age: The age-specific incidence of breast cancer increases steeply with age 
until menopause. After menopause, when ovarian synthesis of estrogens and 
progesterone ceases and ovarian androgen production gradually diminishes, although 
the incidence continues to increase, the rate of increase decreases to approximately 
one-sixth of that seen in the premenopausal period. The dramatic slowing of the rate of 
increase in the age-specific incidence curve suggests that ovarian activity plays a major 
role in the etiology of breast cancer. [3] 
- Exposure to female reproductive hormones and reproductive history: The development 
of breast cancer in many women appears to be related to female reproductive 
hormones. Early age at menarche (before age 12), nulliparity or late age at first full-
term pregnancy (> 30 years), and late age at menopause (after age 55) increase the risk 
of developing breast cancer. Age at menarche and the establishment of regular 
ovulatory cycles are strongly linked to breast cancer risk. Earlier age at menarche is 
associated with an increased risk of breast cancer; there appears to be a 20% decrease 
in breast cancer risk for each year that menarche is delayed. Furthermore, most studies 
suggest that breastfeeding for a year or more slightly reduces a woman’s risk of breast 
cancer. As regards the exposure to exogenous hormones, two major type of hormonal 
compounds have been evaluated in relation to breast cancer: oral contraceptives and 
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menopausal replacement therapy. The evidence suggests a small increase in the 
relative risk associated with the use of combined oral contraceptives and 
postmenopausal hormone replacement therapy (HRT). [3][4] 
- dietary and lifestyle factors: Observational studies suggested that high-caloric diets rich 
in animal fat and proteins were associated with higher rates of breast cancer , 
combined with consumption of alcohol, a lack of physical exercise, overweight and 
obesity (in particular for postmenopausal breast cancer). [3][4][13] 
- environmental factors: only limited data are available on specific exposures in relation to 
breast cancer. Long-term follow-up of women exposed to the Hiroshima or Nagasaki 
nuclear explosions indicates an increased risk of breast cancer, in particular for women 
exposed around puberty. Similarly, exposure as a result of treatment and surveillance 
of tuberculosis is associated with risk. Other environmental factors, including exposure 
to electromagnetic fields and organochlorine pesticides, have been suggested to 
increase breast cancer risk. [3][13] 
- familial factors and inherited predisposition: Women (as well as men) with a family 
history of breast cancer, especially in a first-degree relative (mother, sister, daughter, 
father, or brother), are at increased risk of developing breast cancer; this risk is higher 
if more than one first-degree relative developed breast cancer. Compared to women 
without a family history, risk of breast cancer is 1.8 times higher for women with one 
first-degree female relative who has been diagnosed, nearly 3 times higher for women 
with two relatives, and nearly 4 times higher for women with three or more relatives. 
Risk is further increased when the affected relative was diagnosed at a young age. It is 
important to note that the majority of women with one or more affected first-degree 
relatives will never develop breast cancer and that most women who develop breast 
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cancer do not have a family history of the disease. It is estimated that 5% to 10% of 
breast cancer cases results from inherited mutations, including those in the breast 
cancer susceptibility genes BRCA1 and BRCA2 .[4][13] Other inherited conditions 
associated with smaller increased breast cancer risk include Li-Fraumeni and Cowden 
syndromes and a number of more common genetic mutations [4] 
 
THE PROTEIN SERINE / THREONINE KINASE B (PKB / AKT) IN BREAST CANCER 
AKT, a downstream effector of phosphatidylinositol-3 kinase (PI3K), is one of the most 
frequently hyperactivated protein kinase in human cancer .[33] It is a serine/threonine protein 
kinase and its hyperactivation is associated with resistance to apoptosis, increased cell growth, 
cell proliferation and cell energy metabolism. In mammalian cells AKT comprises three 
highly homologous members (>80% protein sequence identity) termed AKT1/PKBα, 
AKT2/PKBβ and AKT3/PKBγ, encoded by three different genes located on chromosomes 
14q32, 19q13 and 1q43. AKT kinases share the same structural organization, containing an N-
terminal pleckstrin homology (PH) domain, a central catalytic domain and a C-terminal 
regulatory domain that contains the hydrofobic motif (HM). (Figure 5) 
 
Figure 5: Akt domains and comparison of Akt isoforms (% of homology). Chromosome location of each Akt 
isoform in human and phosphorylation sites in Akt1. [35] 
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The PH domain of AKT can bind specifically to D3- phosphorylated phosphoinositides with 
high affinity and mediates AKT activation. [34][35] Analysis of mice lacking either individual 
AKT isoforms or various combinations of AKT isoforms has indicated that the AKT1 isoform 
has a dominant role in embryonic development, fetal growth, and fetal survival, whereas 
AKT2 and AKT3 have non-redundant functions in glucose homeostasis and postnatal brain 
development, respectively. [35] Also the expression of AKT1, AKT2 and AKT3 apparently 
contribute to the different roles of AKT isoforms. AKT1 and AKT2 are widely expressed 
while tissue distribution of AKT3 seems to be more restricted, being primarily expressed in 
brain and testis. [34] 
AKT is activated through receptor tyrosine kinase pathways, through a multi-step PI3K 
dependent process, that involves membrane binding and phosphorilation. Upon activation, 
PI3K produces increased levels of PIP3 (phosphatidylinositol- 3,4,5-trisphosphate) from PIP2 
(phosphatidylinositol-3,4-trisphosphate) which contribute to recruit AKT and PDK1 
(phosphoinositide-dependent kinase 1) to the inner plasma membrane through the pleckstrin 
homology (PH) domain. The interaction of the AKT PH domain with 3’- phosphoinositides is 
thought to impose conformational changes in AKT, exposing its two main phosphorylation 
sites at the kinase domain (T308 for AKT1) and the HM of the C- terminal (S473 for AKT1). 
The direct homodimerization of the two PH domains between AKT and PDK1 might also 
mediate protein proximity and subsequently phosphorylate Thr-308 in AKT, which stabilizes 
the activation loop in an active conformation and renders Ser473 phosphorylation by the 
rapamycin-insensitive mTORC2, resulting in full activation of AKT kinase. [34][35][36]  
Conversely, this activation cascade can be blocked by cellular inhibitors including the 
phosphatase and tensin homolog (PTEN) and INPP4B which directly antagonize PI3K 
function via dephosphorylating PIP3, thereby abrogating PIP3-mediated activation of 
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downstream signaling events such as PDK1 and AKT. However, in vitro engineered AKT 
kinase can override this regulatory mechanism and maintain it in a “supercharged” stage. This 
can be done by insertion of myristoylated (Myr) tag at its N-terminus which results in AKT 
anchoring in plasma membrane and constitutive AKT activation independently of PI3K 
activity. [36] 
Upon activation, AKT leaves the plasma membrane and phosphorylates a number (≈ 9000 
[33]) of substrates both in the cytoplasm and in the nucleus, which mediate AKT-dependent 
regulation of cell growth and survival, mitogenesis, migration, glucose metabolism and protein 
translation. [34] 
Among those substrates are: regulators of cell survival or cell death, such as Bad, caspase-9, 
ASK1, apoptosis signal-regulating kinase 1 (ASK1), forkhead box O transcription factors 
(FoxOs), Bim1, FasL, inhibitor of nuclear factor-κB kinase (IKK-NFκB), and p53; regulators 
of cell cycle progression; such as p21, p27, cyclin D1, and glycogen synthase kinase-3 (GSK-
3α and β); regulators of protein synthesis or cell growth, such as tuberous sclerosis complexes 
1 and 2 (TSC1/2), mTOR, elongation-initiation factor 4E binding protein-1 (4E-BP1), and 
S6K; regulators of angiogenesis, such as mTOR and hypoxia-inducible factor-1 (HIF-1); and 
regulators of cell metabolism, such as glucose transporter 1 (Glut1), GSK3, and a Ras 
homologue enriched in brain (RheB). [34][35] (figure 6) 
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Figure 6: Akt signaling pathway. [37] 
 
 
Mutations in AKT genes are rarely found in human cancers. Activation of AKT acts as a 
survival/proliferative signal; however, activation of AKT alone is generally insufficient to 
induce cancer unless combined with a transforming lesion in a second pathway. For example, 
overexpression of constitutively active human AKT1 in the mouse prostate induces 
precancerous intraepithelial lesions. However, these lesions do not progress even after 78 
months. Overexpression of AKT1 alone in mouse mammary epithelium causes defective 
mammary gland involution, but when expressed with a mutant polyoma virus middle T 
antigen unable to signal through PI3K, the combination produces a marked increase in 
mammary neoplasia. Hyperactivation of AKT signaling occurs in a wide variety of human 
precancerous and cancerous lesions.[37] (figure 7) 
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Figure 7: Alteration in the PI3K/PTEN/AKT pathway in human precancerous lesions. [38] 
 
 
Overexpression and/or activation of AKT in tumor cells causes resistance to traditional 
chemotherapeutics and molecularly targeted drugs, including trastuzumab, gefitinib, retinoic 
acid, and tamoxifen. [38] 
All three AKT isoforms have been associated with tumorigenesis. Overexpression of AKT2 
transforms NIH3T3 fibroblasts and increases the invasive and/or metastatic capacity of human 
cancer cells in vitro and in vivo. [38] Ablation of AKT2 in either HER-2/NEU or polyoma 
middle T transgenic mice decreases metastatic spread. [39] AKT3 activity and expression are 
up-regulated in estrogen receptor-negative breast carcinomas and androgen-insensitive 
prostate cancer cell lines. [40] Selective knockdown of AKT3, but not of other isoforms, 
inhibits melanoma development driven by PTEN loss. In transgenic mice, constitutively active 
AKT1 induces precancerous prostatic lesions and accelerates oncogene-dependent mammary 
tumor formation. [38]  
Deletion of AKT1 reverses the survival phenotype in PTEN null cells and abrogates its growth 
advantage. Similarly, inactivation of AKT by dominant negative mutants inhibits the survival 
advantage provided by activated class I PI3K. Disruption of AKT1 inhibits ErbB2-induced 
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mammary tumorigenesis. AKT1 deficiency delays tumor growth and reduces metastasis. 
AKT1 null mammary epithelial tumor cells have also reduced proliferative capability with 
reduced cyclin D1 and increased p27. These data  suggest that AKT1 plays an important role 
in mammary tumorigenesis. [41]  
The oncogenic activation of AKT1 can be induced by several means, most commonly 
occurring either due to the compromise in its membrane-targeting by PH domain, or due to the 
pathological conformational changes occurring in the mutant structure. Genetic mutations in 
the PH domain alter AKT1 localization and sensitivity to the PtdIns bringing serious 
consequences for its activity.[42] 
A dominant hotspot mutation at nucleotide 49 (G>A) of the gene encoding AKT1 results in 
the substitution of a lysine for glutamic acid at the amino acid 17 (Akt1-E17K). [34][42][43] 
In the apo conformation, Glu 17 occupies the phosphoinositide-binding pocket and forms a 
network of hydrogen bonds. The Lys 17 substitution results in a shift in the surface charge 
around the pocket from negative with Glu 17 to effectively neutral in the mutant. [42][43] The 
AKT1
E17K
 mutation alters the electrostatic interactions of the pocket, activates AKT1 in a 
PI3K-independent manner, increasing level of AKT1 phosphorylation on Thr 308 and Ser 473 
as compared to wild-type. [42][44] AKT1
E17K
 kinase activity was shown to be approximately 
four fold higher than that of AKT1 wild type, suggesting that the mutation alters AKT1 
regulation and hence it enhances cellular activity. [42][43] Furthermore, it has also been 
proposed that the mutation induces large affinity increase for PI(4,5)P2 which is essential to 
the constitutive plasma membrane targeting of the mutant PH domain and thus to the 
oncogenic nature of the full-length AKT1
E17K
 protein. [42] Moreover, it was also suggested 
that the E17K PH domain mutation causes structural changes in the PH domain, which further 
hinders its interaction with AKT1/2 inhibitor VIII. [43] All these observations strongly 
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suggest that the damaging conformational changes in mutant PH domain might cause such 
pathological outcomes. Functionally, the AKT1
E17K
 mutation stimulates AKT signaling, 
induces cellular transformation and produces leukaemia in mice. [44][45] The AKT1
E17K
 
mutation was found in 5 out of 61 (8.2%) breast cancers, 3 out of 51 (5.9%) colorectal 
cancers, 1 out of 50 (2.0%) ovarian cancers [43] and 3 out 105 (2.9%) lung cancer. [46]  
 
GENETICALLY ENGINEERED MOUSE MODELS OF PI3K/AKT SIGNALING IN 
BREAST CANCER 
The role of PI3K/AKT pathway mutations in human breast cancer can be studied using 
genetically engineered mouse models (GEMMs), developed to mimic human genetics of 
breast cancer, with special attention to the role of PI3K/AKT signaling in oncogenesis, 
response and resistance to therapy and metastatic capability. (figure 8) The gene of interest 
(GOI) can be inserted into the host genome in a construct containing a tissue-specific promoter 
to achieve tissue specific expression, such us acidic protein (WAP), beta-lactoglobuli (BLG) 
and mouse mammary tumor virus (MMTV) LTR promoters that are more or less selectively 
active in the mammary epithelial cells. [47] 
 
Figure 8: GEMMs of PI3K-driven breast cancer. [47] 
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Several GEMMs with tissue-specific mutation of PIK3CA, which encodes the 
phosphoinositide-3-kinase (PI3K) catalytic subunit p110α have been published. Several 
groups have shown that expression of the H1047R PIK3CA mutant in luminal mammary 
epithelium results in the formation of mammary tumors of several phenotypes, in particular 
adenosquamous carcinoma or adenomyoepithelioma phenotype. Genetic interaction between 
PIK3CA
H1047R
 and p53 loss-of-function mutations in R26-PIK3CA
H1047R
;p53
loxP/+
;MMTV-Cre 
mice leads to the reduction of survival of double-mutant animals, which developed lymphoma 
and mammary tumors with rapid kinetics. R26-PIK3CA
H1047R
;
p53loxP/+
;MMTV-Cre mammary 
tumors were mostly adenosquamous carcinoma or spindle cell/EMT indicating that double-
mutant mice develop a distinct spectrum of mammary tumors. [47][48] 
In Pten heterozygous knockout (Pten
+/-
) the loss of PTEN expression is associated with basal-
like tumors. [49] Deletion of the Pten gene in mammary epithelium in conditional Pten gene 
knock-out mice, generated by ﬂanking exon 5, which encodes the phosphatase domain of 
PTEN, with LoxP sequences, causes increased cell proliferation, hyper-branched ductal 
structure, precocious development, delayed involution and severely impaired apoptosis. 
PTEN-deﬁcient mammary epithelium also displays remarkable neoplastic changes. [50] 
To examine the role of AKT1 in the etiology of mammary tumorigenesis, transgenic mice 
were generated that express human AKT1 under the control of the mouse mammary tumor 
virus (MMTV) LTR. Ackler et al. have demonstrated for the first time that AKT1 expression 
during lactation results in a pronounced delay in involution, associated with hyperplasia and 
marked expression of cyclin D1. [51] 
Addition of a myristoylation signal to the murine AKT1 gene, which results in AKT1 
anchoring in plasma membrane and constitutive AKT1 activation independently of PI3K 
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activity, increases the incidence of benign lesions, delay in mammary involution and 
susceptibility to epithelial mammary tumor (ER-positive adenocarcinomas or adenosquamous 
tumors) formation induced by the carcinogen 9,10-dimethyl-1,2 benzanthracene (DMBA). 
[52] 
Finally, in double myrAKT;p53(R172H) mice p53 inactivation by R172H point mutation 
combined with myrAKT transgenic expression significantly increases the percentage and size 
of mammary carcinoma, but was not sufficient to promote full penetrance of the tumorigenic 
phenotype. [41] 
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PROJECT'S AIM 
Data from the literature have shown a significant involvement of the PI3K/Akt pathway in the 
onset of breast cancer. The role of AKT1 is controversial, the kinase seems to have a minor 
role, and limited to the ductal breast carcinoma. The purpose of this research project is to 
identify the oncogenic role of AKT1
E17K
 in the mammary tumorigenesis by generating a 
mouse model that expresses AKT1
E17K
 specifically in the breast, with particular attention to 
the effect on cell proliferation and breast cancer stem cells (BCSCs) maintenance. 
Furthermore this project comprises a pharmacological study in order to identify AKT1 as a 
putative target in breast cancer therapy.  
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MATERIALS AND METHODS 
 
RESTRICTION DIGEST OF PLASMID DNA 
Digestion of plasmid DNA was performed using different NEB enzymes. It is preferable to 
digest 0.2-1.5 µg DNA with a 2-fold to 10-fold excess of enzyme in a total volume of 20 µl. In 
the case of double digestion use the most compatible buffer with all the enzymes and it is 
important that the total volume of enzymes add to reaction is not more than 1/10 of the total 
reaction volume. A  
typical restriction enzyme digestion protocol is below: 
- In a 1.5mL tube combine the following: 
 DNA 
 Restriction Enzyme(s) 
 10X Buffer 
 10X BSA (if recommended by manufacturer) 
 dH2O up to total volume (20 µl) 
- Mix gently and spin down briefly 
- Incubate at the optimal reaction temperature (usually 37°C) for 2 hours 
The samples were run in an 1% agarose gel electrophoresis with ethidium bromide, using the 
non-digested plasmid as negative control. 
 
PURIFYING DNA FROM AGAROSE GEL 
Gel purification allows to isolate and purify DNA fragments based on size. The procedure 
starts with standard agarose gel electrophoresis, which separates DNA by their length in base 
pairs. Following electrophoresis, cut DNA bands out of the agarose gel and purify the DNA 
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samples. In our case, for this purpose, we used the QIAGEN QIAquick Gel Extraction Kit, 
using the standard protocol provided by the manufacturer. 
 
DNA LIGATION 
The final step in the construction of a recombinant plasmid is connecting the insert DNA 
(gene or fragment of interest) into a compatibly digested vector backbone. This is 
accomplished by covalently connecting the sugar backbone of the two DNA fragments. This 
reaction, called ligation, is performed by the T4 DNA ligase enzyme. The DNA ligase 
catalyzes the formation of covalent phosphodiester linkages, which permanently join the 
nucleotides together. This experiment was carried out using NEB T4 DNA Ligase (M0202). 
Before setting up the ligation reaction itself, it is important to determine the amount of cut 
insert and vector to use for the ligation reaction. The volume of vector DNA and insert DNA 
used in the ligation will vary depending on the size of each and their concentration. However, 
for most standard cloning (where the insert is smaller than the vector) a 3 insert : 1 vector ratio 
will work just fine.  
To calculate the volume of the insert for the ligation reaction must use the following formula: 
X ng of insert = (3) (bp insert) (50 ng linearized plasmid-) ÷ (size of plasmid in bp) 
- Set up the typical ligation reaction as follows: 
 10X T4 DNA ligase buffer 
 vector DNA 
 insert DNA 
 dH2O up to total volume (20 µl) 
- Gently mix the reaction by pipetting 
- Incubate at 16°C overnight 
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- Chill on ice and transform 1-5 μl of the reaction into 50 μl competent cells. 
 
TRANSFORMATION OF ELECTROCOMPETENT BACTERIAL CELLS 
The electrical transformation refers ingestion of foreign DNA in competent bacterical cells, 
that are able to take exogenous DNA, through the creation of pores in the bacterial cell walls 
using an electrical pulse.  
The transformation protocol requires several steps: 
- Thaw competent cells on ice for defrosting and mix 1 to 5μl of DNA (usually 10pg to 
100ng) into 50μL of competent cells;  
- Add cell/DNA mixture to the electroporation cuvette;  
- Place cuvette in electroporator and shock cells at 2500 V;  
- Remove cuvette from the chamber and immediately add SOC (SOB + glucose 2M). This 
step should be done as quickly as possible to prevent cells from dying off;  
- Transfer SOC-cell mixture to an eppendorf tube and incubate tube in 37°C shaker for at 
least 1 hr to permit expression of antibiotic resistance gene;  
- Centrifuge at 4500 rpm, discard the supernatant and resuspend the bacterial pellet in 100 
μl of LB;  
- Plate transformation onto prewarmed LB-agar plate supplemented with appropriate 
antibiotic and Incubate overnight at 37°C.  
 
RECOVERING PLASMID DNA FROM BACTERIAL CULTURE (MINIPREP) 
After liquid bacteric culture, at 37°C for overnight in a shacking incubator, bacterial cells were 
pelleted by centrifugation at 5000 rpm for 10 minutes. Afterwards, the QIAprep Spin 
Miniprep kit by QIAGEN was used to extract plasmid DNA as manufacturer’s 
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recommendations and resuspended in 30 µl of H2O milliQ. 
 
SITE DIRECTED MUTAGENESIS 
In vitro site-directed mutagenesis has been used to insert the specific mutation in the gene of 
interest. This experiment was performed using stratagene QuikChange Lightning Site-Directed 
Mutagenesis Kit, following the protocol provided and specific oligonucleotides specially 
designed, whose sequences are shown below:   
Mut hAKT1 Fow TGCACAAACGAGGGAAGTACATCAAGACCTG 
Mut hAKT1 Rev CAGGTCTTGATGTACTTCCCTCGTTTGTGCA 
 
 
SOUTHERN BLOT 
- digest 30μg of genomic DNA overnight with desired enzyme; 
- prepare a 0,7% agarose gel with EtBr 0,25μg7μl; 
- load samples with Sounthern Dye; 
- run overnight at 20-50V; 
- take a picture using a ruler; 
- cut marker and wasteful agarose gel; 
- place gel in a bowl with DEPURNATION BUFFER (0,2 N HCl) for the time necessary 
to make the color of the BBF turn from blue to yellow; 
- wash with H2O (2 x 2 min); 
- cut BBF and measure the gel;  
- wash with TRANSFER BUFFER 1 (0,4 NaOH-1 M NaCl) (2 x 15 min); 
- cut a nitrocellulose membrane (Hybond N+) of same dimension of gel, 3MM paper and 
blotting paper; 
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- set up transfer apparatus:elettroforetic apparatus, glass, 3 MM paper; 
- up side down agarose gel and place on nylon membrane, blotting paper and weight; 
- transfer overnight in TRANSFER BUFFER 2 (10X SSC- NaOH 0,1 M); 
- disassemble the blot and mark with a pencil well location on membrane; 
- wash 15 min with NEUTRALIZATION BUFFER (0,5 M Tris-Hcl pH 7,5); 
- dry membrane with 3MM paper; 
- pre-hybridize using dig easy hyb granules roche kit cat. No. 11796895001, for 30 min at 
55°C; 
- hybridize overnight in agitation at 55°C with labeled and denatured probe; 
- wash with WASH BUFFER 1 (2X SSC-0,1% SDS) (2 x 5 min) RT in agitation; 
- wash with WASH BUFFER 2 (0,5X SSC-0,1% SDS) (2 x 15 min) at 65°C in agitation; 
- blocking 30 min  with BLOCKING SOLUTION  (Blocking Reagent Roche Kit Cat. No. 
11096176001 in 1X Maleic Acid 1:10); 
- hybridize 30 min with anti-digoxigenin antibody alkaline phosphatase conjugated; 
- wash with WASH BUFFER (1X Maleic Acid-TRITON) (2 x 15 min); 
- equilibrate with DETECTION BUFFER (0,1 M Tris-HCl-0,1 M NaCl pH 7,5); 
- detect hybridization by chemioluminescence witn CDP-Star kit Roche; 
Previous probe labeling require PCR reaction with PCR DIG Probe Synthesis Kit 
Roche Cat. No. 11636090910, and digoxigenin-conjugated dideoxynucleotides (Dig-
ddUTP) and probe denaturation is carried out at 100°C for 5 minutes. 
 
ISOLATION OF GENOMIC DNA FROM MOUSE TAILS 
- Cut tail pieces (5mm); 
- Add 750 μl lysis buffer (0,05M Tris pH8.0, 1M EDTA, 0,1M NaCl, 1% SDS) and 
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Proteinase K (0,5 mg/ml); 
- Incubate at 60°C overnight; 
- Shake the samples at 1000 rpm at room temperature for 10 minutes; 
- Add 250 μl of 6M NaCl and shake the samples at 1000 rpm at room temperature for 10 
minutes; 
- Centrifuge at 4° C for 10 minutes at full speed; 
- Recover the liquid phase and add dropwise 500 μl of isopropanol; 
- Precipitate DNA by inverting the tube; 
- Spin down DNA at 4° C for 10 minutes at full speed and remove supernatant;  
- Wash pellet with 1 ml of cold 70% ethanol;  
- Spin down genomic DNA at 4° C for 5 minutes at full speed and remove supernatant; 
- Allow DNA to dry for 1-2 minutes; 
- Resuspend DNA in 100-200 μl depending on size of pellet; 
- Place tube at 55°C for 1 hour to facilitate dissolution of DNA. 
 
PCR AMPLIFICATION FOR GENOTYPING 
To determine the genotype of the transgenic mice, we used a PCR protocol with 3 
oligonucleotides.  
The reaction mixture contains: 
- 100 ng DNA;  
- 10X TAQ buffer ;  
- DMSO 2%;  
- dNTP 0,3 mM;  
- TAQ 0,2 U/μl ;  
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- primer mE17K 5’ Arm Fow (SIGMA-ALDRICH) 0,5 μM;  
- primer mE17K Rev New (SIGMA-ALDRICH) 1 μM;  
- primer mE17K 3’ Arm Rev (SIGMA-ALDRICH) 0,4 μM.  
The sequences of the oligonucleotides used are following listed: 
 
                                         5'-3' SEQUENCE  
mE17K 5'ARM Fow AACTGCAGACTTGTGGGATAC 
mE17K 3'ARM Rev ATATTAGTCCACCTCACTCCT 
mE17K 3'ARM Rev New GCCAACCCTCCTTCACAATA 
 
and the amplification program was carried out as below: 
 
 
 
 
 
 
 
 
 
 
FIXATION AND PARAFFIN EMBEDDING OF TISSUE 
- Collect the tissue into a tube containing cold 1X PBS; 
- wash in 1X PBS; 
- Fix the tissue in 10% formalin overnight and proceed with the successive steps: 
 
SOLUTION TIME 
saline solution 1X 3x1h 
saline solution/EtOH 95% 1x30’ +1h 
 
TEMPERATURE TIME 
 1) 95°C 5 min 
 2) 95°C 30 sec 
35 cycles 3) 60°C 30 sec 
4) 72°C 1min 30 sec 
5) 72°C  7 min 
 6) 4°C Forever 
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EtOH 70% 1h 
EtOH 70% o/n 
EtOH 85% 2x1h 
EtOH 95% 2x1h 
EtOH 100% 1h 
EtOH 100% o/n 
Xilene 3x1h 
Xilene/paraffin 2x1h 
Paraffin I 2x30’ 
Paraffin II 50’ 
Paraffin III 1h 
 
Perform paraffin steps at about 60° C and transfer tissue to a mould with paraffin to submerge 
the tissue. Cool at room temperature and store at 4° C. Cut sections (5 µm), mount them on 
coated slides and dry overnight at 37˚ C for subsequent experiments.  
 
HEMATOXYLIN AND EOSIN STAINING PROTOCOL 
- Deparaffinize in Xylene I and II for 10 minutes; 
- Rehydrate: 
- EtOH 100% (5 minutes) 
- EtOH 100% (2 minutes) 
- EtOH 95% (2 minutes) 
- EtOH 95% (2 minutes) 
- EtOH 70% (2 minutes) 
- Rinse in distilled water for 5 minutes; 
- Stain in hematoxylin Harris for 30 seconds;  
- Decolorize in running tap water for 10 minutes;  
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- EtOH 70% for 3 minutes;  
- EtOH 95% for 10 minutes; 
- Counterstain in alcoholic Eosin for 30 seconds;  
- Dehydrate 
- EtOH 95 % (5 minutes) 
- EtOH 100% (10 minutes) 
- Clear in Xylene I and II for10 minutes;  
- Mount with Eukitt BIO-OPTICA. 
RNA EXTRACTION 
To extract RNA from mammary tissue we lysate samples using QIAGEN Tissuelyser for 2 
min at 30 Hz by adding 1 ml of  TRIzol Reagent (Invitrogen) and following the standard 
protocol provided by the manufacturer. The RNA concentration was determined using the 
NanoDrop spectrophotometer.  
 
RT-PCR  
The reverse transcription reaction is performed using Quantitect Reverse Transcription Kit 
(Qiagen). The protocol used requires the following steps: 
- Mix 1 μg of total RNA with gDNA Wipeout Buffer 7X in a final volume of 14 μl; 
- Incubate at 42° C for 2 minutes; 
- Add 1 μl di Quantiscript Reverse Trascriptase, 4 μl di Quantiscript RT Buffer 5X and  
1 μl RT Primer Mix; 
- Incubate at 42°C for 30 minutes and inactivate reaction at 95°C for 3 minutes; 
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REAL-TIME PCR  
The cDNA obtained from the previous reaction of reverse transcription was diluited and used 
to perform a Real-Time quantitative PCR using Sybr Green PCR Master mix (Applied 
Biosystems) to evaluate AKT1 expression levels.  
The reaction mixture contains: 
- 20ng cDNA 
- 0,2 μM primers 
- 2X Sybr Green PCR Master mix 
- MilliQ H2O to 20 μl 
The reaction program is performed using Applied Biosystem 7900 Real-Time PCR System 
and SDS Enterprise Database software and consists of the following steps: 
 
 
TEMPERATURE TIME  
1) 50°C 2 min  
2) 95°C 10 min  
3) 95°C 15 sec 40 cycles 
4) 60°C 1min  
  
The primers sequence used are represented below: 
 
5'-3' SEQUENCE 
GAPDH Fow CCGGGTTCCTATAAATACGGACTGC 
GAPDH Rev CGGCCAAATCCGTTCACACCG 
AKT1 Fow CACACCACCTGACCAAGATG 
AKT1 Rev AATCAAGGGTCCCCAAACTC 
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TOTAL PROTEIN EXTRACTION 
The mammary tissue protein extraction is performed using a specific lysis buffer that allows to 
extract the proteins from the  lipid component typical of the breast tissue. Tissue fragments 
were lysed using QIAGEN Tissuelyser for 2 min at 30 Hz by adding a volume of lysis buffer 
such as to cover the tissue. 
The lysis buffer is consists of the following components: 
- Urea 7 M; 
- Thiourea 2 M;  
- CHAPS 2%;  
- DTT 50mM;  
- Protease inhibitor SIGMAFAST™ 1X;  
- NaF 1 mM;  
- PMSF 1mM;  
- Na3VO4 1mM;  
- Okadaic Acid 15 nM; 
After breaking up with Tissuelyser and short spin to remove tissue debris, the samples were 
incubated on ice for 30 minutes and then centrifuged in a refrigerated centrifuge at 4ºC for 30 
minutes at 13200 rpm. The supernatant was recovered to a microcentrifuge tube and protein 
concentration was determined by a standard Bradford Assay (BioRad) in a Beckman DU 530 
spectrophotometer. 
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WESTERN BLOT 
This technique was used to analyze the protein levels in different samples. 
Polyacrylamide gels were prepared at 10% acrylamide concentrations, according to the 
molecular weight of the proteins in study. After complete polymerization of the gel, it is 
transferred to a electrophoresis tank that was filled with a running buffer containing 25 mM of 
TRIS, 250 mM of Glicine (pH 8.3) and 0.1% of SDS. 50 µg of protein were dispensed in the 
wells, and the gels were run at 100 V. When the proteins were separated between them, the 
run was stopped and fractionated proteins were transferred from the gel to a nitrocellulose 
membrane by Trans-Blot Turbo Transfer System (BIORAD). 
After transferring, the membranes were colored with 1X Red Ponceau (ATX Ponceau S Red 
staining solution, FLUKA) for 1 minute at room temperature to validate the transferring 
homogeneity and quality. Next, the membranes were washed in TTBS (1X TBS and 0,1% 
Tween) and were pre-hybridized for 45 minutes in a solution of TTBS containing 5% Nonfat 
dried milk (AppliChem) to block the non-specific hybridization sites of the primary antibody. 
Subsequently 3 washes of 5 minutes each were made before incubating with the primary 
antibodies diluted in red solution (1X TBS, 3% BSA, 0.02% NaAzide, 100 mg Phenol Red), 
overnight at 4ºC, with agitation. 
The next day, the primary antibody was recovered and the membranes were washed for 5 
minutes, 3 times with TTBS. After that, the membranes were incubated with the respective 
secondary antibody (rabbit or mouse), diluted at 1:2500 in a solution of TTBS with 5% of 
nonfat dried milk, for 1 hour, followed by 3 washes of 5 minutes each with TTBS. Next the 
membranes were incubated for 1 minute with an amplified chemiluminescence kit, ECL 
(Amersham Inc.), which allows the operator to see the chemiluminescence on High 
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performance chemiluminescence film (Amersham Inc.) due to the reaction between the 
substrate present on ECL and the peroxidase covalently bound to the secondary antibody.  
The primary antibodies used in this thesis were the following: 
- Anti-P-AKT (Ser473) antibody (rabbit), 1:1000 (Cell Signaling 
TECHNOLOGY
®
, #4058); 
- Anti-AKT1 antibody (rabbit), 1:1000 (Cell Signaling TECHNOLOGY®, 
#2938); 
- Anti-P-FoxO1 (Ser256) antibody (rabbit), 1:1000 (Cell Signaling 
TECHNOLOGY
®
, #9461); 
- Anti-FoxO1 antibody (rabbit), 1:500 (Cell Signaling TECHNOLOGY®, 
#2880); 
- Anti-P-GSK3α/3β antibody (rabbit), 1:1000 (Cell Signaling TECHNOLOGY®, 
#9331); 
- Anti-GSK3α antibody (rabbit), 1:1000 (Cell Signaling TECHNOLOGY®, 
#9338); 
- Anti-GSK3β antibody (rabbit), 1:1000 (Cell Signaling TECHNOLOGY®, 
#9315); 
- Anti-β-Actin antibody (mouse), 1:10000 (Sigma-Aldrich, A2228) 
  
IHC-PARAFFIN PROTOCOL (IHC-P)  
Before proceeding with the staining protocol, the slides must be deparaffinized and 
rehydrated. Incomplete removal of paraffin can cause poor staining of the section.  
Proceed as follows: 
- incubate slides at 60 overnight. 
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- Deparaffinize in Xylene I and II for 10 minutes. 
- Rehydrate: 
 EtOH 100% (5 minutes) 
 EtOH 100% (2 minutes) 
 EtOH 95% (2 minutes) 
 EtOH 95% (2 minutes) 
 EtOH 70% (2 minutes) 
 PBS 5 minutes  
 PBS+Tween20 5 minutes 
 PBS 5 minutes 
 
- Perform antigen retrieval to unmask the antigenic epitope, using the citrate buffer  
Epitope Retrieval 1X pH=6 Novocastra Leica and incubate slides, immersed in this 
buffer, in the microwave at 900 WATT for 5 minutes and 300 WATT for 5 minutes, 3 
times; 
- Cool at 4° C for 30 minutes; 
- Air dry the slides and wrap with pap pen; 
- Wash in TTBS for 5 minutes, 2 times; 
- Incubate sections in 3% hydrogen peroxide in methanol, for blocking of endogenous 
peroxidase, for 15 minutes; 
- Wash in TTBS for 5 minutes, 2 times; 
- Incubate slides with the primary antibody diluted in Bond Primary Antibody Diluent 
(Leica AR9352), overnight in humidifying chamber; 
- Wash in TTBS for 5 minutes, 2 times. 
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Continue using the kit Novocastra Novolink Polymer Detection Systems (RE7140-K) as 
follows: 
- Novocastra Post Primary Block (RE7111) for 30 minutes; 
- Wash in TTBS for 5 minutes, 2 times; 
- Novolink Polymer (RE7112) for 30 minutes; 
- Wash in TTBS for 5 minutes, 2 times; 
- Develop peroxidase activity with DAB working solution (Ratio 1:20 DAB Chromogen 
RE7105/DAB Substrate Buffer RE7106) maximum for 5 minutes; 
- Rinse slides in water;       
- Counterstain with Hematoxylin RE7107 for 10 minutes;      
- Rinse slides in water for 5 minutes;     
- Dehydrate (EtOH 70%, 80%, 90%, 100%, each from 5 minutes);  
- Clear (xylene 10 minutes, 2 times);  
- Mount sections with Eukitt BIO-OPTICA. 
 
ISOLATION OF VIABLE EPITHELIAL CELLS FROM MURINE  MAMMARY TISSUE 
AND MAMMOSPHERE CULTURES 
- mechanically dissociate mammary tissues into small pieces using a surgical blade and 
placed in a digestion medium (DMEM/F12) supplemented with 200 U/ml collagenase 
(Sigma) and 100 U/ml hyaluronidase (Sigma) for about 5h at 37° C; 
- filtering the cell suspensions through 100, 70, 40 and 20 µm meshes; 
- Centrifuge at 1200 rpm for 5 minutes; 
- Wash the pellet with PBS and centrifuge at 1200 rpm for 5 minutes; 
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Resuspend the pellet in 1-5ml of RBC buffer (NH4Cl 155mM; KHCO3 o NaHCO3 
10mM; EDTA 0,1mM) to eliminate the possible presence of red blood cells; 
- Incubate at RT for 5 minutes; 
- Centrifuge at 1200 rpm for 10 minutes; 
- Wash the pellet with PBS and centrifuge at 1200 rpm for 5 minutes; 
- Count the cells preparing a 1:1 of the cell suspension using a 0,4% Trypan Blue solution. 
Non-viable cells will be blue, viable cells will be unstained.  
Resulting cells were plated onto Corning®Ultra-Low Attachment Surface plates at a density of 
400,000 viable cell/ml (to obtain primary mammospheres) in a serum-free mammary epithelial basal 
medium (MEBM, LONZA), supplemented with 5 µg/ml insulin (Sigma), 0.5 µg/ml hydrocortisone 
(Sigma), B27 (Invitrogen), 20 ng/ml EGF and bFGF (PEPROTECH), and 4 µg/ml heparin (Sigma).  
Mammospheres were collected after 14 days and dissociated with trypsin, to obtain single 
cells derived from mammospheres. For serial passage experiments, 5,000 cells from 
disaggregated primary-mammospheres were plated in 24 multiwell plates and, after 14 days, 
disaggregated and re-plated at the same density. 
 
EVEROLIMUS TREATMENT 
Everolimus (Afinitor®, Novartis), inhibitor of mammalian target of rapamycin (mTOR), was 
dissolved in 12,5% DMSO at a concentration of 1,25 mg/ml (5mg/kg). Virgin 
Akt1
E17K/E17K
;MMTV-Cre female mice, 20-week-old, were treated with two weekly doses of 
EVEROLIMUS, for 8 weeks, via oral gavage. Oral gavage consisted of inserting a curved 
blunt tipped needle attached to a 1 ml syringe into the mid-throat of a ﬁrmly grasped mouse 
and injecting 100 μl of a EVEROLIMUS solution. The control group of virgin 
Akt1
E17K/E17K
;MMTV-Cre female mice was treated with 12,5% DMSO. The mice were 
maintained in the absence of males and were checked by palpation for mammary tumor 
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formation. Mice were sacriﬁced by CO2 inhalation at the end of the period established for the 
experiment and mammary tissue was explanted. 
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RESULTS 
GENERATION OF A Cre-INDUCIBLE  AKT1
E17K 
 MAMMARY MOUSE MODEL 
To investigate the contribution of AKT1
E17K
 mutation in mammary tumorigenesis, we 
generated  a mouse model that, through a Cre/Lox system, expresses the mutated form of 
AKT1 specifically in mammary gland tissue, in time and tissue specific manner. The gene 
targeting strategy allowed us to insert the transgene into the mouse Rosa26 locus, 
preferentially selected for the knock-in strategies as it has a high recombination frequency and 
allows the ubiquitous expression of the inserted gene both in embryonic development and in 
adult mice. The pRosa26 plasmid, containing 5 ' and 3’ homology arms for the specific locus, 
has been suitably modified by adding the following elements: 
- splice acceptor site; 
- Neomycin resistance expression cassette, flanked by two Frt sites;  
- triple SV40 polyadenylation sequence, LoxP- flanked, that prevents the transcription of 
the locus until the elimination of the sequence by the Cre recombinase;  
- β-globin intron and SV40 polyA. 
The human Akt1 cDNA (hAkt1) was inserted into the pBLUScript-KS vector and G>A 
nucleotide substitution was introduced by site-specific mutagenesis. The hAkt1E17K cDNA 
was then inserted into the pRosa26 shuttle vector generating the final construct 
pRosa26hAkt1E17K. The obtained plasmid was linearized and electroporated into mouse 
embryonic stem cells R1/129/Sv. G418-resistant clones were isolated, expanded and screened 
by PCR and Southern Blot. Targeted clones were transiently transfected with Flp recombinase, 
to eliminate the NeoR and allow the expression of the gene. (Figure 9) 
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Figure 9: gene targeting strategy for pRosa26hAkt1E17K construct. A: insertion of the cDNA of interest into the vector 
pBLUScript-KS, B: hAkt1E17K insertion of the cDNA into the Rosa26 locus, C: final recombination of the construct with the 
genomic locus of the murine Rosa26, D: representation of the genomic locus Rosa26 with the insert of interest; E: excision of 
the neomycin resistance cassette by Flp. 
 
The recombined clones were microinjected into C57BL/6 blastocysts for the generation of 
chimeric mice which were crossed with C57BL/6 mice. The presence of the transgene has 
been evaluated by PCR on DNA extracted from tail biopsies. (Figure 10) 
 
 
Figure 10: Genotyping PCR for Rosa26hAKT1E17K/+  mice. The presence of the transgene is represented by the band 
of 1300bp. 
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To activate the expression of AKT1
E17K
 mutant allele in mammary glands, we bred this mouse 
with an MMTV-Cre line (B6129-Tg(MMTV-cre)1Mam/J, #003551; Jackson Laboratory), that 
expresses P1 Cre recombinase under the control of the MMTV-LTR promoter. This mating 
allows high levels of recombination in the virgin and lactating mammary gland. In double 
transgenic mice the deletion of STOP cassette, flanked by two loxP sites, occurs almost 
exclusively at the level of the breast. The occurrence of deletion was verified by PCR on DNA 
extracted from breast biopsies, the mice that have this deletion show a 350-bp PCR product, 
compared to wild-type mice. (Figure 11)  
 
Figure 11: PCR screening to assess the successful deletion of the STOP cassette 
 
CHARACTERIZATION OF AKT1
E17K
 EXPRESSION IN MAMMARY TISSUE 
In order to characterize the generated mouse model for the effective expression of the 
transgene and the activity of AKT1 in Rosa26hAKT1
E17K
;MMTV-Cre mice, we performed a 
Real-Time PCR in which we analyzed the expression of specific transcript, on RNA extracted 
from breast biopsies from Rosa26hAKT1
E17K/E17K
;MMTV-Cre (n=5), 
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Rosa26hAKT1
E17K/+
;MMTV-Cre (n=5) mice. In figure 12 we reported the results of the 
AKT1
E17K
 mRNA quantification in the different mice groups. We observed an increased 
expression of 1.5 times in homozygous respect to the heterozygous transgenic mice. (Figure 
12) 
 
Figure 12: Relative expression of transegene in the different genotype groups of mice 
 
This result was confirmed by analyzing the protein level of AKT1 and, in particular, its 
activation by phosphorylation of residue Ser473, compared to control mice. (Figure 13) 
 
Figure 13: Western blot analysis of protein extracts derived from mammary gland tissue of Rosa26hAKT1E17K;MMTV-Cre 
mice and Rosa26AKT1+/+;MMTV-Cre  mice (T =transgenic mice mammary tissue , C =control mice mammary tissue) 
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The Western Blot analysis shows that in breast tissue derived from transgenic mice AKT1 is 
more expressed compared to control mice and we observed also an elevated accumulation of 
phospho-AKT1
Ser473
. In order to evaluate the effect of AKT1
E17K
 on epithelial breast cells 
proliferation we performed a trypan blue viability assay on single cells suspension derived 
from transgenic and control mice. We observed that the presence of AKT1
E17K
 causes a 5 fold 
increased tissue cellularity in heterozygous transgenic mice compared to control mice while in 
homozygous transgenic mice the cellularity of breast tissue is almost 10 fold increased 
compared to control mice. (Figure 14) 
 
Figure 14: Analysis of mammary gland tissue cellularity derived from the different genotype groups of mice 
 
AKT1
E17K
 EXPRESSION IS ONCOGENIC IN MAMMARY TISSUE 
To asses the potential role of AKT1 as oncogene in mammary epithelium, we examined the 
consequences of AKT1
E17K
 expression in mammary gland in Rosa26hAKT1
E17K
;MMTV-Cre 
mice. First of all, we evaluated the possible appearance of tumors in 
Rosa26hAKT1
E17K
;MMTV-Cre virgin females compared to Rosa26AKT1
+/+
;MMTV-Cre, for 
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a period of 15 months. At the end point (15 months), we observed that 70% (15/21) of 
Rosa26hAKT1
E17K
;MMTV-Cre mice developed mammary tumors, single or multiple, 
indicating a high incidence of cancer that is strictly dependent on the presence of the 
transgene. This data has been correlated with a survival analysis, which allowed us to monitor 
temporally the occurrence of tumors. The mice are monitored by fat pad palpation and were 
sacrificed when the tumors have achieved certain sizes. The data obtained have allowed us to 
perform a statistical analysis of survival, through a Kaplan-Meier curve. The data show a 
reduction in the overall survival of mice expressing the mutation AKT1
E17K
, with a peak of 
mortality between 10 and 12 months. (Figure 15) 
 
Figure 15: Survival curve of Rosa26hAKT1E17K;MMTV-Cre and Rosa26AKT1+/+;MMTV-Cre mice, computed using the 
Kaplan-Meier method. 
 
Tumors harvested from mice, that may affect both thoracic that inguino-abdominal mammary 
glands,  and the counterpart of healthy breast tissue, if present, were histologically 
characterized. The tissue biopsies were fixed in formalin, paraffin embedded and subjected to 
hematoxylin/eosin staining. Histological analysis of tumor sections of 
Rosa26hAKT1
E17K
;MMTV-Cre mice shows the presence of ductal carcinomas from medium 
to high grade. Furthermore, transgenic mice that do not have a visible tumor show an 
alteration of mammary epithelium which goes from hyperplastic lesion to dysplasia. The 
figure (Figure 16) shows representative images of mammary tumors derived from 
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Rosa26hAKT1
E17K
;MMTV-Cre mice compared with the mammary epithelium of 
Rosa26AKT1
+/+
;MMTV-Cre control mice, which present the typical morphology of breast 
tissue, consists of a lipidic reticulum with glandular units composed by a lumen surrounded by 
a single cell layer.  
 
 
Figure 16: hematoxylin-eosing staining of representative normal (up) and tumoral (down) breast tissue  
 
Analysis of the tumors from Rosa26hAKT1
E17K
;MMTV-Cre mice allowed us to confirm 
literature data that report the presence of the mutated form AKT1
E17K
 especially in human 
ductal breast carcinomas. 
To test the PI3K pathway activation, lysate from representative tumors of 
Rosa26hAKT1
E17K
;MMTV-Cre mice were analyzed for phosphorilation status of AKT1 and 
its downstream effectors, such as FOXO1 and GSK3α/β and cyclin D1. Total protein extract 
from tumors were compared with those derived from healthy counterparts and breast tissue of 
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control mice. In the proteins derived from tumors is observed an increased phosphorylation of 
AKT1 than control tissues. In all tumors analyzed we observed elevated levels of phospho-
FOXO1
Ser256
 and phospho-GSK3α/βSer21/9 and high levels of cyclin D1. (Figure 17)  
 
 
 
Figure 17: Western blot of AKT1 and downstream effects in tumor derived from Rosa26hAKT1E17K; MMTV-Cre mice 
compared to healthy counterparts and normal breast tissue from control mice. 
 
The elevated level of AKT1 phosphorylation was confirmed by immunohistochemistry on 
paraffin embedded sections of breast cancer from Rosa26hAKT1
E17K
;MMTV-Cre mice 
compared with their healthy counterparts. This histological analysis showed that tumors from 
transgenic mice were characterized by hyperactivation of AKT1. (Figure 18)  
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Figure 18: anti p-AKTSer473 and AKT1 staining of paraffin embedded sections of breast cancer from 
Rosa26hAKT1E17K;MMTV-Cre mice compared with their healthy counterparts. 
 
 
AKT1
E17K
 CONTRIBUTION IN THE GENERATION AND MAINTEINANCE OF 
PUTATIVE BREAST CANCER STEM CELLS 
In tumors has been identified a subpopulation of cells, called cancer stem cells (CSCs) with 
stem cell characteristics, probably responsible for the formation and maintenance of the tumor, 
metastases and chemoresistance. This cell subpopulation has also been identified in breast 
cancer (breast cancer stem cells, BCSCs) and several studies have demonstrated the 
implication of PI3K/AKT pathway in BCSCs biology. [29][31] Putative BCSCs can be 
identified through their ability to proliferate as spheroid structures in non-adherent conditions. 
To analyze the AKT1
E17K
 role in BCSCs we performed a mammosphere formation assay. 
Homogeneous cell suspension derived from non cancerous mammary tissue of 
Rosa26hAKT1
E17K/E17K
;MMTV-Cre, Rosa26hAKT1
E17K/+
;MMTV-Cre and 
40X 40X 
40X 40X 
AKT1 
 
P-AKT
Ser473 
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Rosa26AKT1
+/+
;MMTV-Cre mice were seeded in non-adherent condition, serum-free medium 
supplemented with B27, EGF and FGF. After about 10 days the single cell suspension 
generated floating colonies called "mammospheres". (Figure 19) 
 
Figure 19: representative images of mammospheres derived from Rosa26AKT1+/+;MMTV-Cre,(a) 
Rosa26hAKT1E17K/+;MMTV-Cre(b) and Rosa26hAKT1E17K/E17K;MMTV-Cre mice(c).  
 
We observed that cells derived from Rosa26hAKT1
E17K/+
;MMTV-Cre and 
Rosa26hAKT1
E17K/E17K
;MMTV-Cre mice generated a number of mammospheres 2.5 and 8 
fold increased, respectively, compared to Rosa26AKT1
+/+
;MMTV-Cre mice. Size analysis of 
the mammospheres revealed that the spheroids derived from Rosa26hAKT1
E17K/+
;MMTV-Cre 
and Rosa26hAKT1
E17K/E17K
;MMTV-Cre mice showed a diameter of 1.5 and 2 folds increased, 
respectively, compared to spheroid generated by single cells from Rosa26AKT1
+/+
;MMTV-
Cre mice (Figure 20) 
 
b a c 
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Figure 20:cumulative number and size measurement of mammospheres derived from the different mice groups.  
 
To test the self-renewal capability of the mammosphere-forming cells during generations, the 
primary mammospheres were dissociated into single cells and  replated in the same conditions. 
Mammospheres derived from Rosa26AKT1
+/+
;MMTV-Cre mice were regenerated for only 
four generations, while those derived from Rosa26hAKT1
E17K/E17K
;MMTV Cre are capable to 
regenerate the spherois until eight generations. (Figure 21) 
 
Figure 21: graphic representation of capability to regenerate spheroids of putative BCSCs from Rosa26AKT1+/+;MMTV-Cre 
and Rosa26hAKT1E17K/E17K;MMTV Cre mice. 
 
AKT1
E17K
 IS A PUTATIVE TARGET IN BREAST CANCER THERAPY 
We performed a pharmacological study to identify a therapeutic strategy in order to target 
PI3K/AKT pathway for breast cancer treatment. Recently has been developed a new drug, 
Everolimus, for the treatment of advanced stage ER+, HER2- mammary carcinomas. The 
Everolimus is a selective inibitor of mTOR (mammalian target of rapamycin),  a serine-
threonine kinase, whose activity is upregulated in several cancers. The activation of the mTOR 
complex-1 (mTORC1) is downstream of AKT signaling. Everolimus binds the intracellular 
protein FKBP-12, forming a complex that inhibits mTORC1. Four-five months-old 
Rosa26hAKT1
E17K/E17K
;MMTV-Cre mice (n=8) are treated with Everolimus (5mg/kg, 
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gavage), for 8 weeks (2 doses in week), as control we treated a group of mice (n=9) with the 
vehicle. At the end of treatment, the breast tissue of both groups was collected and subjected 
to histological analysis. We observed that 66.7% (6/9) of the control mice developed tumors 
and 11,1% (1/9) severe dysplasia, while only 37.8% (3/8) of treated mice with Everolimus 
showed medium-grade dysplasia.  
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DISCUSSION 
 Breast cancer is the most common female malignancy and the leading cause of cancer death 
in women. It is caused by the combination of genetic and environmental factors. Specific 
inherited mutations in BRCA1 and BRCA2 increase the risk of breast cancers. Together, 
BRCA1 and BRCA2 mutations account for about 20-25% of hereditary breast cancers and 
about 5-10% of all breast cancers. [54][55] In the onset of sporadic breast cancer are involved 
gene alterations in oncogenes and tumor suppressors genes. Among these, the 
phosphoinositide-3 kinase (PI3K) pathway has been identified to have an important role. The 
importance of this pathway in tumorigenesis is represented by the high frequency of  his 
activativation in cancer, as illustrated in Figure 7. In the figure are showed the tumors in which 
this pathway is upregulated by mutations. In addition some of the components have an 
intrinsic inhibitory effect, such as phosphatase and tensin homologue deleted on chromosome 
ten (PTEN). [56] In particular in breast cancer mutations in the components of the PI3K/AKT  
pathway occur in the 25% of the cases. The majority of mutations are in PIK3CA, encoding 
the catalytic p110α subunit, and are nonrandomly localized in three “hot spots,” resulting in 
single amino acid substitutions: E545K and E542K in the helical domain (exon 9) and 
H1047R in the kinase domain (exon 20). These mutations increase enzymatic function, 
enhance downstream signaling elements, including AKT, and promote oncogenic 
transformation. [18] 
In hormone receptor–positive tumors, these mutations occur in >30% of cases. Also, in 
HER2+ disease, mutations are evident in about one quarter of tumors. Meanwhile, it seems 
that mutations in triple-negative breast cancer may be less frequent. [3] More recently a single 
hotspot mutation, G49A:E17K, in the pleckstrin homology domain of AKT1 was described, 
predominantly in human breast tumors. [43] The reported frequency of this mutation has 
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ranged from 1.8%–8%. [18] [43][44][45] Importantly, mutant AKT1 is able to activate PI3K 
signaling pathway and to transform rodent fibroblasts and bone marrow cells . [43] Most 
studies have found PTEN, PIK3CA, and AKT1 mutations to be mutually exclusive in 
individual tumors [43][44][49], suggesting that mutational activation of the PI3K/AKT 
pathway by any one of the components are biologically equivalent.  
Until now the role of AKT1 in mammary tumorigenesis represents a  secondary event. In vivo 
studies have shown that its hyperactivated form, myrAKT1, which results in AKT anchoring 
to the plasma membrane and constitutive activation, delay the mammary involution and 
increases the incidence of benign lesions. In addition myristoylation signal increases the 
susceptibility to epithelial mammary tumor formation after induction by the carcinogen 9,10-
dimethyl-1,2 benzanthracene (DMBA). [52] Somewhat surprisingly, published data 
demonstrated that overexpression of AKT1 is able to transform cells in vitro[43], but the 
knock-in of mutant AKT1
E17K
 in MCF10A cells failed to recapitulate this capacity. [53] These 
findings are similar to what  was observed with knock in of mutant KRAS and may reflect 
differences between knock in and transgenic overexpression as well as differences between 
cell types in their susceptibility to transformation. However, were not made in vivo studies to 
analyze the effect of mutant form of AKT1 in mammary tumorigenesis. For this reason the 
aim of this study is the evaluation of the role of AKT1
E17K
 in the mammary tumorigenesis in a 
mouse model that expressed AKT1
E17K
 specifically in mammary gland tissue. These mice are 
derived by crossing Rosa26AKT1
E17K
 transgenic mice with an MMTV-Cre mouse line. The 
resulting mice, Rosa26hAKT1
E17K
;MMTV-Cre, drive the expression of AKT1
E17K
 almost 
exclusively in the mammary tissue.  
The data from this study showed that the transgene was expressed primarily in the mammary 
gland. This is consistent with the findings that increase in MMTV-LTR transcriptional activity 
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is through mammary development and during pregnancy. [57] The hAKT1
E17K
 specific 
transcript was expressed in mammary gland of trangenic mice compared to the control 
littermates. In addition, the analysis of the expression of AKT1
E17K
 in breast tissue derived 
from transgenic mice demonstrates that the transgene expression is increased from 
heterozygous to homozygous mice. These results are confirmed by the analisys of downstream 
pathway activation status, phosphorylation of AKT1 is higher than that wild-type control 
mice.  
The activation of AKT1 by overexpression or myristoylation signal has been shown to delay 
mammary gland involution and induce hyperplasia [51]. This process accelerates mammary 
tumorigenesis in MMTV-c-ErbB2 mice [58] but overexpressing or activated AKT1 in 
mammary gland alone is not able to induce dysplasia and neoplasia [59][60]. Activation of 
AKT1 induces oncogenic transformation upon exposure to carcinogens [52]. Surprisingly, in 
our model, we demonstrated that transgenic mice with active AKT1 led to a significant higher 
incidence of mammary carcinoma without exposure to the carcinogen insults. In particular 
tumor incidence was of about 70%, starting from four months of age, with a peak of mortality 
between 10 and 12 months. The histological analysis conducted on the explanted mammary 
tumor masses revealed that the tumors are ductal carcinomas from medium to high grade, 
confirming the literature data from breast cancer patients showing the presence of the mutant 
AKT1
E17K
 in ductal and lobular carcinomas. [43] The tumor tissues from transgenic mice had 
increased phosphorylated AKT1 at Ser473 and the tumors derived from 
Rosa26hAKT1
E17K
;MMTV-Cre mice showed hyperactivation of the PI3K/Akt pathway.  
Increased pAKT
Ser473
 was associated with strong phosphorilation levels of downstream 
substrates as FOXO1 and GSK3α/β. Moreover tumor tissues from transgenic mice 
overexpress cyclin D1. Cyclin D1 plays role in tumor cell proliferation, migration and was 
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inversely correlated with tumor size in human breast cancer [61] Overexpression of cyclin D1 
has been reported between 40% and 90% of cases of invasive breast cancer, while gene 
amplification is seen in about 5–20% of tumors [35]. Increase in protein level of cyclin D1 
was apparent in hyperplasia and further increased with malignancy. [62][63] Cyclin D1 has 
also been shown as an essential oncogenic intermediary for Neu pathway inducing mammary 
carcinoma in transgenic mice. [64][65]. In our model, we observed that cyclin D1 expression 
was higher in Rosa26hAKT1
E17K
;MMTV-Cre mice driven mammary carcinoma, compared to 
control mice. The histological analysis revealed also the presence of preneoplastic lesions, 
from hyperplasia to dysplasia. These results, associated with the activation of AKT pathway, 
correlates the presence of mutant AKT1 to the cell proliferation, in vivo. Mammary gland 
derived from 8-12 weeks Rosa26hAKT1
E17K
;MMTV-Cre mice showed increased cellularity, 
ten fold increased compared to mammary tissue derived from control littermates.  
It has been recently suggested that a cellular subpopulation with stem cell (SC)-like features, 
known as Cancer Stem Cells (CSCs), is critical for tumor generation and maintenance, and 
responsible for breast cancer metastasis. [24] In vitro and in vivo evidences revealed the 
importance of PTEN/PI3K/Akt/Wnt/β-catenin pathway in breast cancer stem cells (BCSCs) 
biology. Increased AKT Ser473 phosphorylation in suspension culture of putative breast 
cancer stem cells (mammospheres) as compared with monolayer cultures, determines 
increased levels of GSK3-β phosphorylation and β -catenin activation. β-catenin has been 
demonstrated to play an important role in the development of mammary stem cells in mouse 
models, suggesting that this pathway may also be active in human mammary stem/progenitor 
cells in mammospheres. [31] To assess the role of AKT1
E17K
 in the context of BCSCs, we 
exploited his ability to regulates the growth of cells suspension, derived from 
Rosa26hAKT1
E17K
;MMTV-Cre an control mammary gland tissue, in spheroid conditions. 
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Performing a mammospheres assay we observed that cells derived from 
Rosa26hAKT1
E17K
;MMTV-Cre mice generates increased number of mammospheres 
compared to those derived from control mice. Furthermore the mammospheres derived from 
transgenic mice showed a diameter two fold increased compared to the wild-type mice. The 
self-renewal assay revealed that cells derived from  Rosa26hAKT1
E17K
;MMTV-Cre mice are 
capable to renew until 8 generations the spheroid culture. The obtained data allow us to 
identify an important role of AKT1
E17K
 in mammary tumorigenesis and in the maintenance of 
the tumor through its involvement in the biology of the BCSCs. We therefore conducted a 
pharmacological study in which we evaluated the antitumor activity of the drug Everolimus on 
tumor induction and / or progression of breast cancer in Rosa26hAKT1
E17K/E17K
;MMTV-Cre 
mice. This drug has recently been developed for the treatment of breast cancers in advanced 
phase, positive estrogen receptor and HER2 negative. Everolimus is a selective inhibitor of 
mTOR (mammalian target of rapamycin) a serine-threonine kinase whose activity is known to 
be upregulated in several human cancers. The activation of this complex is downstream of 
AKT, which can act in a direct manner on mTOR, through phosphorylation at the residue 
Ser2448, and in indirectly, by inactivating phosphorylation at residue Thr246 of PRAS40, a 
inhibitory component of the mTORC1 complex and at the level of 5 residues (S939, S981, 
S1130, S1132 and T1462) of TSC2, which together with TSC1 constitutes a complex that 
inhibits mTOR via RHEB protein. [35] Treatment with this drug has allowed to inhibit, or at 
least slow down, the complete transformation of breast tissue in  Rosa26hAKT1
E17K
;MMTV-
Cre mice.   
In summary this project led us to these results: i) the generation of a new mouse model for 
breast cancer, AKT1-dependent; ii) the analysis of the mouse models revealed that the 
activation of AKT1 in mammary tissue increases the risk of development of mammary tumors  
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iii) the involvement of AKT1
E17K
 in the generation and maintenance of BCSCs; iiii) 
Rosa26hAKT1
E17K
;MMTV-Cre transgenic mouse is a valuable resource for understanding the 
mechanisms of breast cancer target therapy. 
Future experiments will be needed for the molecular characterization of mammary tumors 
induced by AKT1
E17K
. We will also confirm the stemness of mammospheres derived cells, 
testing their positivity to stem marker (such us Sox2, Oct4, Nanog), their symmetric and 
asymmetric division and their in vivo tumorigenic capability.  
 64 
BIBLIOGRAPHY 
1) Orlando E Silva, Stefano Zurrida: “Breast cancer: a pratical guide”, 3rd edition 2005, 
ch 3; 
2) Ahmedin Jemal, Freddie Bray, Melissa M. Center, Jacques Ferlay, Elizabeth Ward, 
David Forman: “Global Cancer Statistics”, CA CANCER J CLIN 2011;61:69–90; 
3) Fattaneh A. Tavassoli and Peter Devilee: “Pathology and Genetics of Tumours of the 
Breast and Female Genital organs”, World Health Organization Classification of 
Tumours, 4th edition 2003, ISBN 9283224124; 
4) American Association for cancer Research, AACR: “Breast Cancer Facts & Figures 
2013-2014”; Atlanta American Cancer Society, Inc . 2013; 
5) D. Craig Allred: “Ductal Carcinoma In Situ: Terminology, Classification, and Natural 
History”, J Natl Cancer Inst Monogr 2010;41:134–138; 
6) Yee Vonne Liong, Ga Sze Hong, Jennifer Gek Choo Teo and Geok Hoon Lim: “Breast 
ductal carcinoma in situ presenting as recurrent non-puerperal mastitis: case report 
and literature review”, World Journal of Surgical Oncology 2013, 11:179; 
7) Kilbride KE, Newman LA. Chapter 25: Lobular carcinoma in situ: Clinical 
management. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of 
the Breast. 4th edition 2010;  
8) www.breastcancer.org; 
 65 
9) Grazia Arpino, Valerie J Bardou, Gary M Clark and Richard M Elledge: “Infiltrating 
lobular carcinoma of the breast: tumor characteristics and clinical outcome”, Breast 
Cancer Res 2004, 6:R149-R156;  
 
10) S. Eva Singletary, Lina Patel-Parekh and Kirby I. Bland: “Treatment Trends in Early-
Stage Invasive Lobular Carcinoma A Report From the National Cancer Data Base”, 
Annals of Surgery, Volume 242, Number 2, August 2005; 
11) Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, 
Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, 
Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, 
Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, 
Pant PV, Ballinger DG, Sparks AB, Hartigan J, Smith DR, Suh E, Papadopoulos N, 
Buckhaults P, Markowitz SD, Parmigiani G, Kinzler KW, Velculescu VE, Vogelstein 
B.: “The Genomic Landscapes Of Human Breast And Colorectal Cancers”, Science 
2007 Nov 16;318(5853):1108-13; 
12) Turner NC, Reis-Filho JS.: “Basal-like breast cancer and the BRCA1 phenotype”, 
Oncogene. 2006 Sep 25;25(43):5846-53;  
13) Vincent T DeVita, Jr.,  Theodore S Lawrence,  Steven A Rosenberg,  Ronald A 
DePinho,  Robert A Weinberg: “DeVita, Hellman, and Rosenberg's Cancer: Principles 
& Practice of Oncology”, 9th edition 2011, ch 105-106;  
 66 
14) Foulkes WD.: “Inherited Susceptibility To Common Cancers”, N Engl J Med. 2008 
Nov 13;359(20):2143-53; 
15) Stratton MR, Rahman N.:”The Emerging Landscape Of Breast Cancer Susceptibility”. 
Nat Genet 2008;40(1):17;  
16) Turnbull C, Rahman N.Genetic “Predisposition To Breast Cancer: Past, Present, And 
Future”. Annu Rev Genomics Hum Genet 2008;9:321;  
 
17) Kim M. Hirshﬁeld, Timothy R. Rebbeck, and Arnold J. Levine: “Germline Mutations 
and Polymorphisms in the Origins of Cancers in Women”, Journal of Oncology 
Volume 2010, Article ID 297671;  
18) K. Stemke-Hale, A.M. Gonzalez-Angulo, A. Lluch, et al., “An integrative genomic and 
proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer” Cancer 
Research, vol. 68, no. 15, pp. 6084–6091, 2008;  
19) Charles M. Perou and Anne-Lise Børresen-Dale: “Systems Biology and Genomics of 
Breast Cancer”, Cold Spring Harb Perspect Biol 2011;3:a003293; 
20) M.J. Engstrøm, S. Opdahl, A.I. Hagen, P.R. Romundstad, L.A. Akslen, O.A. Haugen, 
L.J. Vatten, A.M. Boﬁn: “Molecular subtypes, histopathological grade and survival in 
a historic cohort of breast cancer patients”, Breast Cancer Res Treat (2013) 140:463–
473;  
21) Britta Weigelt, Johannes L. Peterse and Laura J. van’t Veer: “Breast cancer 
metastasis: markers and models”,  Nature Reviews, Cancer, Volume 5, 2005; 
 67 
22) Linda Vona-Davis, David P. Rose, Vijaya Gadiyaram, Barbara Ducatman, Gerald 
Hobbs, Hannah Hazard, Sobha Kurian and Jame Abraham: “Breast Cancer Pathology, 
Receptor Status, and Patterns of Metastasis in a Rural Appalachian Population”,  
Journal of Cancer Epidemiology,Volume 2014, Article ID 170634;  
23) Osama Hussein & Svetlana V. Komarova: “Breast cancer at bone metastatic sites: 
recent discoveries and treatment targets”,  J. Cell Commun. Signal. (2011) 5:85–99; 
24) M Bartucci, R Dattilo, C Moriconi, A Pagliuca, M Mottolese, G Federici, A Di 
Benedetto, M Todaro, G Stassi, F Sperati, MI Amabile, E Pilozzi, M Patrizii, M 
Biffoni, M Maugeri-Saccà, S Piccolo and R De Maria: “TAZ is required for metastatic 
activity and chemoresistance of breast cancer stem cells”,  Oncogene (2014), 1 – 10;   
25) Marco A. Velasco-Velázquez, Nora Homsi, Marisol De La Fuente, and Richard G. 
Pestell: “Breast Cancer Stem Cells”,  Int J Biochem Cell Biol. 2012; 
26) Robert W. Cho, Xinhao Wang, Maximilian Diehn, Kerby Shedden, Grace Y. Chen, 
Gavin Sherlock, Austin Gurney, John Lewicki, Michael F. Clarke: “Isolation and 
Molecular Characterization of Cancer Stem Cells in MMTV-Wnt-1 Murine Breast 
Tumors” STEM CELLS 2008;26:364 –371; 
27) Muhammad Al-Hajj, Max S. Wicha, Adalberto Benito-Hernandez, Sean J. Morrison 
and Michael F. Clarke: “Prospective identification of tumorigenic breast cancer 
cells”,PNAS May 27, 2003; 
28) Kazuharu Kai, Yoshimi Arima, Toshio Kamiya, Hideyuki Saya: “Breast cancer stem 
cells”, Breast Cancer April 2010;  
 68 
29) Marco A. Velasco-Velázquez, Vladimir M. Popov, Michael P. Lisanti and Richard G. 
Pestell: “The Role of Breast Cancer Stem Cells in Metastasis and Therapeutic 
Implications”,  The American Journal of Pathology, Vol. 179, No. 1, July 2011; 
30) Jay R Harris ,  Marc E Lippman,  C. Kent Osborne,  Monica Morrow: “Diseases of the 
Breast”, 4th edition 2009; 
31) Hasan Korkaya, Amanda Paulson, Emmanuelle Charafe-Jauffret, Christophe Ginestier, 
Marty Brown, Julie Dutcher, Shawn G. Clouthier, Max S. Wicha: “Regulation of 
Mammary Stem/Progenitor Cells by PTEN/ Akt/β-Catenin Signaling” , PLoS Biology, 
2009;  
32) Steven P. Zielske, Aaron C. Spalding, Max S. Wicha and Theodore S. Lawrence: 
“Ablation of Breast Cancer Stem Cells with Radiation”, Translational Oncology 
(2011) 4, 227–233;  
  
33) X Wan, B Harkavy, N Shen, P Grohar and LJ Helman: “Rapamycin induces feedback 
activation of Akt signaling through an IGF-1R-dependent mechanism”, Oncogene 
(2007) 26, 1932–1940;  
34) Viglietto G, Amodio N, Malanga D, Scrima M, De Marco C: “Contribution of 
PKB/AKT signaling to thyroid cancer”, Front Biosci (Landmark Ed). 2011 Jan 
1;16:1461-87;  
35) Liao Y, Hung MC: “Physiological regulation of Akt activity and stability”, Am J 
Transl Res. 2010 Jan 1;2(1):19-42;  
 69 
36) Peng Z, Weber JC, Han Z, Shen R, Zhou W, Scott JR, Chan MW, Lin HJ: “Dichotomy 
effects of Akt signaling in breast cancer”, Molecular Cancer 2012, 11:61;  
37) Michael A. Davies, The University of Texas MD Anderson Cancer Center, Houston, 
TX: “Regulation, Role, and Targeting of Akt in Cancer”, Journal Of Clinical 
Oncology,  Volume 29, Number 35, 2011;  
38) James A. Crowell, Vernon E. Steele and Judith R. Fay: “Targeting the AKT protein 
kinase for cancer chemoprevention”, Molecular Cancer Therapy 2007;6:2139-2148;  
39) Maroulakou IG, Oemler W, Naber SP, Tsichlis PN.: “Akt1 ablation inhibits, whereas 
Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse 
mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic 
mice”. Cancer Res 2007;67:167 – 77; 
40) Nakatani K, Thompson DA, Barthel A., et al.: “Up-regulation of Akt3 in estrogen 
receptor-deficient breast cancers and androgen-independent prostate cancer lines”. J 
Biol Chem 1999;274:21528 – 32; 
41) Carmen Blanco-Aparicio, Marta Cañamero, Yolanda Cecilia, Belén Pequeño1, Oliver 
Renner, Irene Ferrer, Amancio Carnero: “Exploring the Gain of Function Contribution 
of AKT to Mammary Tumorigenesis in Mouse Models”, PLoS ONE, February 2010, 
Volume 5, Issue 2, e9305;  
42) Ambuj Kumar, Rituraj Purohit: “Cancer Associated E17K Mutation Causes Rapid 
Conformational Drift in AKT1 Pleckstrin Homology (PH) Domain”, PLOS ONE, May 
2013, Volume 8, Issue 5, e64364;  
 70 
43) Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, 
Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, 
Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, 
Blanchard KL, Thomas JE: “A transforming mutation in the pleckstrin homology 
domain of AKT1 in cancer”, Nature. 2007 Jul 26;448(7152):439-44;  
44) FE Bleeker, L Felicioni, F Buttitta, S Lamba, L Cardone, M Rodolfo, A Scarpa, S 
Leenstra, M Frattini, M Barbareschi, M Del Grammastro, MG Sciarrotta, C Zanon, A 
Marchetti and A Bardelli: “AKT1E17K in human solid tumours”,  Oncogene (2008) 27, 
5648–5650;  
45) MS Kim, EG Jeong, NJ Yoo and SH Lee: “Mutational analysis of oncogenic AKT 
E17K mutation in common solid cancers and acute leukaemias”, British Journal of 
Cancer (2008) 98, 1533 – 1535; 
46) Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, de Gisi S et al.: “Activating 
E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous 
cell carcinoma of the lung”, Cell Cycle (2008)5: 665–669;  
47) Sjoerd Klarenbeek, Martine H. van Miltenburg, Jos Jonkers: “Genetically engineered 
mouse models of PI3K signaling in breast cancer”, Molecular Oncology 2013, 146 
e164; 
 
48) W Yuan, E Stawiski, V Janakiraman, E Chan, S Durinck, KA Edgar, NM Kljavin, CS 
Rivers, F Gnad, M Roose-Girma, PM Haverty, G Fedorowicz, S Heldens, RH Soriano, 
 71 
Z Zhang, JJ Wallin, L Johnson, M Merchant, Z Modrusan, HM Stern and S Seshagiri: 
“Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary 
tumorigenesis and emergence of mutations”, Oncogene 2013, 32, 318 – 326;  
49) Lao H Saal, Sofia K Gruvberger-Saal, Camilla Persson, Kristina Lövgren, Mervi 
Jumppanen, Johan Staaf, Göran Jönsson, Maira M Pires, Matthew Maurer, Karolina 
Holm, Susan Koujak, Shivakumar Subramaniyam, Johan Vallon-Christersson, Haökan 
Olsson, Tao Su, Lorenzo Memeo, Thomas Ludwig, Stephen P Ethier, Morten Krogh, 
Matthias Szabolcs, Vundavalli VVS Murty, Jorma Isola, Hanina Hibshoosh, Ramon 
Parsons, and Åke Borg:  “Recurrent gross mutations of the PTEN tumor suppressor 
gene in breast cancers with deficient DSB repair”, Nature Genetics 2008 January ; 
40(1): 102–107;  
50) Gang Li, Gertraud W. Robinson, Ralf Lesche, Hilda Martinez-Diaz, Zhaorong Jiang, 
Nora Rozengurt, Kay-Uwe Wagner, De-Chang Wu, Timothy F. Lane, Xin Liu, Lothar 
Hennighausen and Hong Wu: “Conditional loss of PTEN leads to precocious 
development and neoplasia in the mammary gland”, Development 2002, 129, 4159-
4170; 
51) Scott Ackler, Shakeel Ahmad, Christopher Tobias, Michael D Johnson and Robert I 
Glazer: “Delayed mammary gland involution in MMTV-AKT1 transgenic mice”, 
Oncogene 2002, 21, 198-206;   
52) Carmen Blanco-Aparicio, Lucìa Pérez-Gallego, Belén Pequeño, Juan F.M.Leal, Oliver 
Renner and Amancio Carnero: “Mice expressing myrAKT1 in the mammary gland 
 72 
develop carcinogen-induced ER-positive mammary tumors that mimic human breast 
cancer”, Carcinogenesis vol.28 no.3 pp.584–594, 2007;  
53) Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay 
JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak 
K, Cowherd M, Buckhaults PJ, Park BH: “Knock in of the AKT1 E17K mutation in 
human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations”, 
Oncogene. 2010 Apr 22;29(16):2337-45; 
54) Easton DF. “How many more breast cancer predisposition genes are there?” Breast 
Cancer Research 1999; 1(1):14–17; 
55) Campeau PM, Foulkes WD, Tischkowitz MD. Hereditary breast cancer: “New genetic 
developments, new therapeutic avenues”. Human Genetics 2008; 124(1):31–42; 
56)   Torres-Arzayus MI, de Mora JF, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, 
and Brown M: “High tumor incidence and activation of the PI3K/AKT pathway in 
transgenic mice define AIB1 as an oncogene”. Cancer cell 2004, 6:263-274;  
57) Torres-Arzayus MI, de Mora JF, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, 
and Brown M: “High tumor incidence and activation of the PI3K/AKT pathway in 
transgenic mice define AIB1 as an oncogene”. Cancer cell 2004, 6:263-274; 
58) Young CD. Nolte EC, Lewis A, Serkova NJ, and Anderson SM: “Activated Akt1 
accelerates MMTV-c-EebB2 mammary tumorigenesis in mice without activation of 
ErbB3”. Breast Cancer Res 2008, 10:R70;  
 73 
59) Sinn E. Muller W, Pattengale P, Tepler I, Wallace R, and Leder P: “Coexpression of 
MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of 
oncogene in vivo”. Cell 1987, 49: 465-475; 
60) Hutchinson J, Jin J, Cardiff RD, Woodgett JR, and Muller WJ: “Activation of Akt 
(protein kinase B) in mammary epithelium provides a critical cell survival signal 
required for tumor progression”. Mol. Cell Biol 2001, 21:2203-2212; 
61) Lehn S, Tobin NP, Berglund P, Nilsson K, Sims AH, Jirstrom K, Harkonen P, Lamb R, 
and Landberg G: “Down-regulation of the oncogene cyclin D1 increases migratory 
capacity in breast cancer and is linked to unfavorable prognostic features”. Am J 
Pathol 2010, 177:2886-2897; 
62) Roy PG, Thompson AM: “Cyclin D1 and breast cancer”. Review. The Breast 2006, 
15:718–727; 
63) Sutherland RL. and Musgrove EA: “Cyclin D1 and mammary carcinoma: new insights 
from transgenic mouse models”. Breast Cancer Res 2002, 4:14-17; 
64) Hutchinson JN, and Muller WJ: “Transgenic mouse models of human breast cancer”. 
Oncogene 2000, 19:6130-6137; 
65) Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, 
Kung AL, Boehmer HV, and Sicinski P: “The Requirement for Cyclin D Function in 
Tumor Maintenance”. Cancer Cell 2012, 22:438–451. 
 
 
 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
